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HELICOBACTER PYLORI
Promoter methylation of E-cadherin gene in gastric
mucosa associated with Helicobacter pylori infection and
in gastric cancer
A O-O Chan, S-K Lam, B C-Y Wong, W-M Wong, M-F Yuen, Y-H Yeung, W-M Hui,
A Rashid, Y-L Kwong
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Background: E-cadherin is an adhesion molecule involved in tumour invasion/metastasis. Silencing of
E-cadherin by promoter CpG methylation has been shown in both familial and sporadic gastric can-
cers. Helicobacter pylori is a class I carcinogen in gastric cancer.
Aims: This study was undertaken to investigate the association between methylation of E-cadherin and
H pylori in gastric mucosa from dyspeptic patients, and in intestinal metaplasia and primary and meta-
static adenocarcinoma from surgical specimens of patients with gastric cancer.
Methods: E-cadherin methylation was studied using methylation specific polymerase chain reaction in
microdissected tissue from biopsies or surgical resection specimens. E-cadherin expression was studied
by immunohistochemistry.
Results: E-cadherin methylation was present in 31% (11/35) of gastric mucosae from dyspeptic
patients, and was associated with H pylori infection (p=0.002), but was independent of the age of the
patient or presence or absence of gastritis. E-cadherin methylation was present in 0% (0/8) of normal
mucosa, 57% (12/21) of intestinal metaplasias, and 58% (15/26) of primary and 65% (21/32) of
metastatic cancers. E-cadherin methylation status was concordant in 92% (11/12) of intestinal meta-
plasias and primary cancers, and in 85% (17/20) of primary and metastatic cancers from the same
resected specimen. E-cadherin methylation in gastric cancer was associated with depth of tumour inva-
sion (p=0.02) and regional nodal metastasis (p=0.05).
Conclusion: E-cadherin methylation is an early event in gastric carcinogenesis, and is initiated by H
pylori infection.
E-cadherin is a transmembrane glycoprotein expressed onepithelial cells, and is responsible for calcium dependenthomotypic cell adhesion. It binds to several cytosolic pro-
teins including α-, β-, and γ-catenins, which are in turn linked
to actins.1 2 Cell-cell and cell-matrix interactions are crucially
involved in neoplastic transformation and metastasis.3–6
Defective cell adhesion may contribute to loss of contact inhi-
bition of growth, which is an important early step in the neo-
plastic process. Furthermore, loss of cell adhesion may
account for the ability of cancer cells to cross normal tissue
boundaries and metastasise. The importance of E-cadherin in
maintaining cell adhesion implies that its dysfunction may
play an important part in tumorigenesis.7
In gastric carcinogenesis, the critical role of E-cadherin is
underlined by the observation that familial gastric cancer is
related to germline mutation of the E-cadherin gene.8 9
Furthermore, somatic mutations of E-cadherin were found in
approximately 50% of gastric carcinoma of the diffuse
histological type.10 Finally, in two kindreds with familial
gastric cancer and germline E-cadherin mutation, promoter
CpG hypermethylation was found to be the second “genetic
hit” in abrogating E-cadherin expression.11 These results show
that E- cadherin is an important putative tumour suppressor
gene involved in gastric carcinogenesis.
Gastric carcinogenesis is a multistep process with morpho-
logical progression involving multiple genetic and epigenetic
events, and an intestinal metaplasia-dysplasia-invasive carci-
noma sequence exists.12 It is now increasingly recognised that
epigenetic silencing of gene expression by promoter CpG
hypermethylation is an important alternative mechanism in
inactivating tumour suppressor genes and tumour associated
genes in cancers,13 and in gastric cancers and precursors.14 15
Helicobacter pylori infection is an important aetiological risk
factor in gastric cancer, and has been classified as a group I or
definite carcinogen by the World Health Organization’s Inter-
national Agency for Research on Cancer.16
In this study, we evaluated the role of E-cadherin methyla-
tion in dyspeptic patients without metaplasia or dysplasia, and
in sporadic gastric carcinomas, by studying promoter hyper-
methylation of the gene in gastric mucosa in patients without
cancer, in intestinal metaplasia, and in primary carcinoma and
metastatic lymph nodes from patients undergoing surgery for
gastric cancer. In particular, the association between
E-cadherin methylation and H pylori was assessed.
MATERIALS AND METHODS
Patients and specimens
Thirty five gastric mucosal biopsies obtained from patients
undergoing upper endoscopy for dyspepsia were studied. Hae-
matoxylin and eosin stained slides were evaluated for the
presence of gastritis, intestinal metaplasia, or dysplasia. H
pylori infection was evaluated by histology and urease breath
test. DNA from eight normal mucosae, 21 intestinal metapla-
sias, and 26 primary adenocarcinomas and 32 metastatic
lymph nodes from gastrectomy specimens of patients under-
going resection for gastric adenocarcinoma were studied. The
tumours were staged according to the Japanese Research
Society for Gastric Cancer17 and classified according to the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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World Health Organization classification scheme.18 DNA was
obtained by microdissection from 5 µm thick haematoxylin
and eosin stained paraffin embedded tissue sections without
coverslip, as described previously.19 H pylori infection status
was evaluated in 18 primary adenocarcinoma specimens by
histology. Informed consent for tissue procurement was
obtained from all patients.
Methylation specific polymerase chain reaction (MSP)
for E-cadherin promoter methylation
The methylation status of the E-cadherin promoter was deter-
mined by bisulphite treatment of DNA followed by MSP, as
described previously.20 Briefly, 2 µg of DNA were denatured
with 2 M NaOH at 37°C for 10 minutes, followed by incubation
with 3 M sodium bisulphite, pH 5.0, at 50°C for 16 hours.
Bisulphite treated DNA was then purified (DNA Cleanup Kit;
Promega, Madison, Wisconsin, USA), incubated with 3 M
NaOH at room temperature for five minutes, precipitated with
10 M ammonium acetate and 100% ethanol, washed with 70%
ethanol, and resuspended in 20 µl of distilled water. DNA (2
µl) was then amplified by polymerase chain reaction (PCR)
with two sets of primers specific for the methylated and
unmethylated alleles, as described by Herman and
colleagues20 and Graff and colleagues21 (fig 1). CpGenome
Universal Methylated DNA (Intergen, Purchase, New York,
USA) in which E-cadherin was methylated and reagent blanks
were used as positive and negative controls in each
experiment. All tests were performed in duplicate. For confir-
mation of the specificity of MSP, PCR products from the meth-
ylated and unmethylated primers were gel purified and
sequenced, as previously described.22
Immunohistochemical staining for E-cadherin
E-cadherin expression was examined by immunostaining
using the avidin-biotin complex immunoperoxidase
method.23 Briefly, 4 µm thick tissue slides were deparaffinised
in xylene and rehydrated serially with alcohol and water.
Endogenous peroxidase was blocked with 3% hydrogen
peroxide for 10 minutes, followed by microwave antigen
retrieval for nine minutes at 95°C in 10 mM sodium citrate
buffer, pH 6.0. The slides were then incubated with an avidin
conjugated monoclonal anti-E-cadherin antibody (HECD-1
1:500 dilution in phosphate buffered saline; Zymed Laborato-
ries Inc., South San Francisco, USA) in a moist chamber at
37°C for one hour. Bound antibody was detected by a
biotinylated secondary antibody and the avidin-biotin com-
plex immunoperoxidase method (Dako Corp., Carpinteria,
USA). The slides were finally counterstained with Mayer’s
haematoxylin. For a negative control, the primary antibody
was replaced with mouse IgG. Slides with normal gastric
mucosa were used as a positive control. Furthermore, positive
E-cadherin staining in the adjacent non-involved gastric
mucosa served as an internal positive control. E-cadherin
staining was classified as absent staining, cytoplasmic
distribution, heterogeneous staining, or normal membranous
staining. Because staining patterns often varied within the
same tumour, particularly when the degree of differentiation
varied, the classification was based on the dominant pattern.
Tumours with more than 10% variation were scored as hetero-
genous.
Statistical analysis
Fisher’s exact test and χ2 test were used to compare categori-
cal associations and the Student’s t test for continuous
associations. Two sided tests were used to calculate p values.
Multivariate analysis using a forward conditional model was
used to evaluate the contribution of age, gastritis, and H pylori
infection to E-cadherin methylation in the gastric mucosae of
patients with dyspepsia. The relationship between E-cadherin
methylation status and clinicopathological features, including
age, histological subtypes of the carcinoma, depth of tumour
invasion, presence and extent of regional lymph node, and
distant metastasis, were evaluated in the 26 primary cancers.
RESULTS
MSP for E-cadherin
MSP with both sets of primers for the methylated and
unmethylated E-cadherin promoter gave expected results in
Figure 1 (A) Confirmation of the specificity of methylation specific polymerase chain reaction (MSP). The wild-type E-cadherin gene sequence
is shown together with the sequence of the methylated polymerase chain reaction (PCR) product. M1: PCR product (shown here from
nucleotides 2280 to 2339, Genbank accession No D49685) with first primer set, as described by Herman and colleagues,20 for the methyl-
ated E-cadherin allele (forward primer: 5′- TTA GGT TAG AGG GTT ATC GCG T -3′; reverse primer: 5′- TAA CTA AAA ATT CAC CTA CCG
ACC -3′). Primers for the unmethylated E-cadherin allele were forward: 5′- TAA TTT TAG GTT AGA GGG TTA TTG T -3′; reverse: 5′- CAC
AAC CAA TCA ACA ACA CA -3′. In the MSP product, methylated cytosine residues that are unchanged are underlined in blue, and the
unmethylated cytosine residues that have become uracil/thymidine are underlined in red. (B) M2: PCR product from second primer set for meth-
ylated E-cadherin allele (shown here from nucleotides 2229 to 2283), as described by Graff and colleagues21, for the methylated E-cadherin
allele (forward primer: 5′- GTG GGC GGG TCG TTA GTT TC -3′; reverse primer: 5′- CTC ACA AAT ACT TTA CAA TTC CGA CG -3′). Prim-
ers for the unmethylated E-cadherin allele were forward: 5′- GGT GGG TGG GTT GTT AGT TTT GT -3′; reverse: 5′- AAC TCA CAA ATC TTT
ACA ATT CCA ACA -3′.
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the positive and negative controls, and concordant results in
all of the tested specimens. Sequencing of the PCR products
confirmed the expected nucleotide changes associated with
bisulphite modification in the methylated and unmethylated
alleles (fig 1A, 1B).
E-cadherin methylation, expression, and
clinicopathological associations in gastric mucosae
from patients with dyspepsia
The clinicopathological associations of 35 patients with
dyspepsia are tabulated in table 1. Gastritis was present in 31
(89%) cases, and H pylori infection in 19 (54%) cases. Patients
with H pylori infection were older compared with those with-
out infection (53 (14) years v 38 (12) years; p=0.002). H pylori
infection was also associated with gastritis (p=0.009). Intesti-
nal metaplasia or dysplasia was not present in any biopsy on
histological assessment. E-cadherin methylation in gastric
mucosa was present in 11 (31%) patients (fig 2A, 2B). All 11
cases with E-cadherin methylation had gastritis (NS) (table 1).
E- cadherin methylation was associated with H pylori infection:
53% (10/19) of patients with H pylori infection had E-cadherin
methylation versus 94% (15/16) of patients without H pylori
infection and no methylation (p=0.002) (table 1). Patients
with E-cadherin methylation were older compared with those
without methylation (53 (13) years v 43 (15) years; p=0.048).
H pylori infection was the only factor associated with
E-cadherin methylation by multivariate analysis (p=0.013
(95% confidence interval 0.007–0.55)). However, immuno-
histochemical staining showed normal membranous staining
of E-cadherin in samples with or without E- cadherin methyla-
tion. This was probably due to the fact that immunohisto-
chemical staining was not as sensitive as PCR in detecting
subpopulations of cells with gene methylation and hence
downregulation of E-cadherin.
E-cadherin methylation, expression, and
clinicopathological associations in resected specimens
in patients with gastric cancer
E-cadherin methylation was present in 0 of 8 (0%) normal
mucosae, 12 of 21 (57%) intestinal metaplasias, 15 of 26 (58%)
primary cancers, and 21 of 32 (65%) metastatic cancers (fig
2C). Methylation status was concordant between 11 of 12
(92%) intestinal metaplasias and cancers, and 17 of 20 (85%)
primary and metastatic cancers from the same patients. One
patient had methylation in intestinal metaplasia but not
primary cancer, another had unmethylated primary cancer
but methylated metastatic cancer, and two patients had meth-
ylated primary cancer but unmethylated metastatic cancer.
E-cadherin immunohistochemistry was performed on 13 pri-
mary and nine metastatic cancers. Eleven primary cancers had
loss of membranous distribution of E-cadherin (fig 3A) and
had E- cadherin methylation (100%). Of two primary cancers
with retained E-cadherin expression, the gene was methylated
in one case and unmethylated in the other. Seven metastatic
cancers in the lymph node had diminished E-cadherin stain-
ing (fig 3B), and five (71%) had E- cadherin methylation. In the
two remaining cancers with retained E-cadherin expression,
the gene was methylated in one cancer and unmethylated in
the other. E-cadherin methylation was associated with the
depth of tumour invasion. All three tumours confined to the
lamina propria (T1) were unmethylated but 15 of 23 (65%)
tumours with invasion of the muscularis propria or beyond
were methylated (p=0.02) (table 2). E-cadherin methylation
was also associated with regional nodal metastasis. Four of
five (80%) patients without nodal metastasis were unmethyl-
ated but 14 of 21 (67%) patients with regional metastasis were
methylated (p=0.05) (table 2). However, methylation was not
related to age,H pylori infection status, histological subtype, or
distant metastasis status.
Discussion
In this study, we found E-cadherin methylation in patients with
H pylori infection without metaplasia or dysplasia, in intestinal
metaplasia, and in primary and metastatic cancers from
patients undergoing gastrectomy for gastric cancer. E-cadherin
methylation was present in one third of gastric mucosae from
patients with dyspepsia, and was associated with age and H
pylori infection. However, by multivariate analysis H pylori
infection was the only significant contributing factor. H pylori
can induce transcriptional activation by inflammatory media-
tors such as nuclear factor κB and cyclooxygenase 2 (COX-
2).24 25 Methylation in gastric epithelial cells may occur as a
consequence of or as an adaptive protective response due to
chronic exposure to inflammatory mediators overproduced
during infection, a mechanism that has been described in viral
infection,26 or in metaplasia, dysplasia, and carcinoma
developing due to chronic reflux injury of the oesophagus and
inflammatory bowel disease in the colorectal region.27 28 The
former is supported by a previous study which showed that H
Table 1 Association of E-cadherin promoter
methylation with age, gastritis, and Helicobacter pylori
infection status in 35 patients with dyspepsia
E-cadherin
Methylated
(No (%))
Unmethylated
(No (%)) p Value
Age (y)* 53 (13) 43 (15) 0.048
Chronic gastritis
Present 11 (35) 20 (65) NS
Absent 0 (0) 4 (100)
H pylori
Present 10 (53) 9 (47) 0.002
Absent 1 (6) 15 (94)
*Mean (SD).
Figure 2 (A) Analysis of methylation of E-cadherin in gastric
mucosae from patients with dyspepsia. Samples N3–N6 are
methylated, and samples N1, N2, and N7 are unmethylated.
Methylation specific polymerase chain reaction (MSP) was
performed with the first primer set, resulting in a methylated
polymerase chain reaction (PCR) product of 116 bp and an
unmethylated PCR product of 97 bp. (B) Analysis of methylation of
E-cadherin in gastric mucosae from patients with dyspepsia, as
shown in (A), but with MSP performed with the second primer set.
Samples N3–N6 are methylated, and samples N1, N2, and N7 are
unmethylated. (C) Analysis of methylation of E-cadherin in intestinal
metaplasia (IM), gastric adenocarcinomas (T), and metastatic lymph
nodes (LN) from patients with gastric cancer. Samples IM2, T1, T2,
LN1, and LN2 are methylated, and sample IM1 is unmethylated.
MSP was performed with the first primer set.
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pylori stimulated COX-2 expression in gastric cell lines without
promoter methylation of the COX2 gene but not in cell lines
with methylation of COX-2 promoter.25 However, COX-2
expression can be induced by demethylation treatment with
5-azacytidine followed by exposure to H pylori in cell lines with
methylation of COX-2 promoter. It is therefore possible that
E-cadherin methylation may be mediated through similar
mechanisms in response to H pylori infection. Finally, it is
intriguing to note that only about half of gastritis cases with H
pylori infection showed E-cadherin methylation. This could be
related to a sampling effect as E-cadherin methylation in rela-
tion to H pylori infection might be focal. Alternatively, other
collaborative mechanisms together with H pylori infection may
be involved in E-cadherin methylation.
Also, it is apparent that only a small proportion of H pylori
related gastritis cases progress to carcinoma. According to
Knudson’s “two hit” hypothesis,29 two genetic mutations are
required for inactivation of a putative tumour suppressor
gene. Promoter methylation with suppression of gene expres-
sion may collaborate with mutation or deletion to cause gene
inactivation, thereby fulfilling Knudson’s hypothesis.30 Thus
the occurrence of additional genetic events may be necessary
for E-cadherin gene inactivation, leading to initiation of
carcinogenesis.
We did not observe an association between H pylori infection
and E-cadherin methylation in gastric cancers. This may be
related to the fact that this was a retrospective analysis so that
prior H pylori infection status was not known in all of the cases
of cancer. However, it is also well known that H pylori infection
declines with the development of gastric cancer31 and
histological examination alone cannot reflect accurately
previous exposure to H pylori infection.
E-cadherin methylation was present in 57% of intestinal
metaplasias in patients with gastric cancers in our study. The
timing of hypermethylation during tumour development may
vary among different genes and tumour types. Kang and
colleagues15 demonstrated that methylation at DAP-kinase,
THBS1, and TIMP-3 was present in gastritis whereas p16 and
hMLH1 were present in intestinal metaplasia and cancer. We
demonstrated that the frequency of E-cadherin methylation
was the highest compared with the methylation frequency at
p16 (2.1%), hMLH1 (6.3%), THBS-1 (34.7%), DAP-kinase
(36.7%), and TIMP-3 (36.7%) in intestinal metaplasia.15
Methylation of E-cadherin was present in 58% of primary
cancers and 66% of cancers metastatic to lymph nodes in our
study, a frequency comparable with previous reports.14
Interestingly, in the metastatic nodes without E-cadherin
methylation, there were two cases where the primary tumour
showed E-cadherin methylation. Similar findings have been
observed in immunohistochemical studies of E-cadherin
expression.23 It has been postulated that expression of
E-cadherin might be dynamic. Thus downregulation of
E-cadherin in the primary tumour may allow cell dispersal
into the circulation while re-expression of E- cadherin may
allow cell deposition at distant sites to form metastases.23
There was, in general, concordance between E-cadherin
methylation and diminished E- cadherin expression by
Figure 3 Immunohistochemical staining for E-cadherin, showing (A) membranous distribution of staining in the normal gastric mucosa, (B)
cytoplasmic staining in gastric cancer cells, and (C) cytoplasmic staining in neoplastic cells in a metastatic lymph node.
Table 2 Clinicopathological associations of
E-cadherin methylation in patients with gastric cancer
Clinicopathological
parameter
E-cadherin
p ValueMethylated (%) Unmethylated (%)
Age (y)* 65 (14) 58 (13) NS
H pylori
Present 6 (67%) 3 (33%) NS
Absent 5 (56%) 4 (44%)
Histological subtype
Mucinous/signet
ring
8 (80%) 2 (20%) NS
Tubular 7(44%) 9 (56%)
Regional nodal
metastasis
N0 1 (20%) 4 (80%) 0.05
N1/N2 14 (67%) 7 (33%)
Depth of invasion
T1 0 (0%) 3 (100%) 0.02
T2/T3/4 15 (65%) 8 (35%)
Distant metastasis
Present 2 (50%) 2 (50%) NS
Absent 13 (59%) 9 (41%)
*Mean (SD).
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immunostaining. However, there was one primary and one
metastatic cancer in a lymph node where E-cadherin methyla-
tion was not associated with diminished E- cadherin staining.
This may indicate that cancer cells with E-cadherin methyla-
tion were only a minor subclone of the tumour, which was
picked up by the sensitive MSP.
Clinicopathological correlations showed that E-cadherin
methylation was associated with depth of invasion and nodal
metastasis. This pattern suggests that increasing acquisition
of E- cadherin methylation may be related to progressive
tumour development. If E-cadherin methylation is also an
important initiating event, as occurs in intestinal metaplasia
progressing to gastric cancer, a quantitative increase in
E-cadherin methylation may be expected as the neoplastic
clone progressively increases in size. To further validate these
possibilities, analysis of E-cadherin methylation by a quantita-
tive assay is required.32 These biological considerations
notwithstanding, depth of invasion and nodal metastasis in
relation to E-cadherin methylation were parameters that may
be associated with poor prognosis. In fact, the role of
E-cadherin as a prognostic marker in gastric cancer has been
previously shown by immunohistochemical studies23 33 and
serum enzyme linked immunosorbant assays.34 Furthermore,
loss of E-cadherin expression is most pronounced in epithelial
carcinomas with an infiltrative growth pattern associated with
no intercellular cohesion, such as invasive lobular breast can-
cer and diffuse-type gastric adenocarcinoma. The increased
invasiveness of tumours with E-cadherin methylation identi-
fied in our study might be consistent with these findings.
In conclusion, we have shown an association between
E-cadherin methylation in the stomach and H pylori infection in
dyspeptic patients without cancer, and in intestinal metapla-
sia and cancer. Furthermore, E-cadherin methylation in gastric
cancer was also associated with depth of tumour invasion and
nodal metastasis in gastric adenocarcinoma. However, the
results of this study do not exclude mechanisms other than H
pylori infection that may lead independently to E-cadherin
methylation. A working hypothesis may be that gastric
mucosal infection by H pylori initiates E-cadherin methylation
which may subsequently progress to intestinal metaplasia and
invasive cancer. Such a hypothesis will require vigorous
testing in future studies. Finally, the potential contribution of
E-cadherin methylation to other H pylori related pathologies
may warrant further investigation.
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